Paxlovid: abin da muka sani game da kwayar Pfizer's Covid-19

Pfizer yana neman izinin amfani da gaggawa daga FDA don sabon littafin sa na maganin rigakafi na Covid-19 Paxlovid.
Raba Labari

Dangane da amincewar Merck antiviral molnupiravir ta Burtaniya, Pfizer ta tashi don samun nata kwayar cutar ta Covid-19, Paxlovid, a kasuwa.A wannan makon, mai sayar da magunguna na Amurka ya nemi izinin amfani da gaggawa daga Hukumar Abinci da Magunguna ta Amurka (FDA) don sabon ɗan takararta na rigakafin ƙwayar cuta a cikin mutanen da ke da Covid-19 mai sauƙi zuwa matsakaici, waɗanda ke cikin haɗarin asibiti ko mutuwa. Pfizer ya kuma ya fara aiwatar da neman izinin doka a wasu ƙasashe ciki har da Birtaniya, Australia, New Zealand da Koriya ta Kudu, da kuma shirin yin ƙarin aikace-aikace. Yaya Paxlovid ke aiki? Ritonavir, maganin rigakafin cutar kanjamau da aka saba amfani da shi don magance cutar kanjamau.Maganin yana rushe kwafin SARS-CoV-2 a cikin jiki ta hanyar ɗaure ga 3CL-kamar protease, wani enzyme mai mahimmanci ga aikin ƙwayar cuta da haifuwa.
Dangane da wani bincike na wucin gadi, Paxlovid ya rage haɗarin asibiti da ke da alaƙa da Covid-19 ko mutuwa da kashi 89% a cikin waɗanda suka karɓi magani cikin kwanaki uku na bayyanar cutar.An gano miyagun ƙwayoyi yana da tasiri sosai - kawai 1% na marasa lafiya waɗanda suka karɓi Paxlovid an kwantar da su ta hanyar rana ta 28 idan aka kwatanta da 6.7% na mahalarta placebo-cewa an ƙare gwajin sa na Mataki na II/III da wuri kuma an gabatar da ƙaddamar da ka'idoji ga FDA da wuri fiye da ana sa ran.Bugu da ƙari, yayin da aka ba da rahoton mutuwar 10 a kan hannun placebo, babu wanda ya faru a cikin mahalarta da suka karbi Paxlovid.Kamar molnupiravir, Paxlovid ana gudanar da shi ta baki, ma'ana marassa lafiyar Covid-19 na iya shan maganin a gida a farkon matakan kamuwa da cuta.Fatan shi ne cewa sabbin magungunan rigakafi kamar na Merck da Pfizer za su ba da damar a yi wa mutanen da ke fama da cutar sankara ko matsakaiciyar cutar coronavirus da wuri a yi musu magani da wuri, da hana ci gaban cututtuka da kuma taimakawa wajen guje wa kamuwa da asibitoci.

Gasar magunguna ta Covid-19Merck's molnupiravir, kwaya ta farko da aka amince da ita don Covid-19, an yi la'akari da shi mai yuwuwar canza wasa tun lokacin da bincike ya gano ya rage yawan asibiti da haɗarin mace-mace da kusan kashi 50%.Amma wannan ba yana nufin kyautar rigakafin ƙwayar cuta ta Pfizer ba za ta sami ci gaba a kasuwa ba.Binciken wucin gadi na ingancin molnupiravir yana da alƙawarin, amma raguwar haɗarin da Pfizer ya bayar ya nuna cewa kwayayen nata na iya tabbatar da wani muhimmin makami a cikin makaman gwamnatocin yaƙi da cutar. kishiya antiviral.Wasu ƙwararrun sun bayyana damuwa cewa tsarin aikin molnupiravir akan Covid-19 - kwaikwayon ƙwayoyin RNA don haifar da maye gurbi - na iya haifar da maye gurbi a cikin DNA na ɗan adam.Paxlovid, wani nau'in antiviral daban-daban da aka sani da mai hana protease, bai nuna alamun "mutagenic hulɗar DNA", in ji Pfizer.